McDonald’s Sees Flat Traffic, Sticky Inflation as New Normal 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
H&M Q3 Profit Beats Estimates as Margins Improve 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
Russian Missile and Drone Attack on Kyiv Kills Two, Damages Maternity Hospital 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
Kremlin Says No Decision Yet on Putin-Trump December Summit 
Novartis Shares Plunge After Muscle Drug Fails Phase III Trial 
Najib Razak Seeks Stay of 15-Year 1MDB Prison Sentence 
GLP-1 Weight-Loss Drug Use Surges Among U.S. Children 
Ghana Says Western Support Growing for Slave Trade Reparations 
Yemen Violence Displaces 130,000 as Civilian Toll Rises 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
OpenAI Agent Breaches Australia Medicare Data Portal 
Meta Connect Spotlights Camera-Free Smart Glasses Amid Privacy Concerns 
Add as a preferred source on Google
Novo Nordisk has named U.S. pharmaceutical executive Greg Miley as its new Global Head of Corporate Affairs, a strategic move as the Danish drugmaker faces heightened scrutiny from U.S. President Donald Trump over drug pricing. Miley, formerly Senior Vice President of Government Affairs at AbbVie, announced his appointment on LinkedIn, with Novo Nordisk confirming the news to Reuters.
The company stated that Miley will officially join in early November, overseeing global communications and public affairs. His extensive experience in the U.S. pharmaceutical sector is expected to help Novo strengthen its political and regulatory strategies in its largest market—the United States. A company source noted that Miley’s top priority will be managing relations with the Trump administration, which has recently intensified pressure on pharmaceutical firms to reduce prices.
Miley’s appointment aligns with new CEO Mike Doustdar’s efforts to regain investor confidence through a broad restructuring initiative aimed at improving competitiveness in the growing obesity drug market, particularly against Eli Lilly. The overhaul involves cutting about 9,000 jobs worldwide, including 5,000 in Denmark and several in the U.S.
In his LinkedIn post, Miley expressed optimism about enhancing Novo’s global communication and public affairs, noting his upcoming relocation to Denmark. Industry insiders say other major pharma companies have also been recruiting public affairs experts with strong Republican ties to navigate Washington’s policy landscape.
Shares of Novo Nordisk and Eli Lilly dropped on Friday following Trump’s statement that the price of Ozempic—Novo’s diabetes drug containing the same ingredient as its popular weight-loss drug Wegovy—would be lowered.
Miley brings nearly two decades of experience in pharmaceutical government relations, with past roles at Abbott and Pfizer, making him a pivotal figure in Novo’s next phase of global engagement.
